NZYM B Novozymes A/S Class B

Novozymes launches new biosolution to redefine the plant-based meat experience by enhancing texture and encouraging more consumers to choose plant-based alternatives

Novozymes launches new biosolution to redefine the plant-based meat experience by enhancing texture and encouraging more consumers to choose plant-based alternatives

Novozymes is excited to offer Vertera® ProBite as a game-changing solution to the plant-based meat industry, opening up new possibilities to create today's and tomorrow's plant-based meat products with advanced texture and consumer-friendly labels. The new product is a part of Novozymes’ commitment to driving innovation in biosolutions and promoting sustainable food choices.

Copenhagen – September 28: Today marks an important milestone in the evolution of plant-based meat innovation with the launch of Vertera® ProBite, a solution set to advance the plant-based meat industry by changing the need for manufacturers’ use of unwanted texturizers to a natural alternative. Developed by global biosolutions provider, Novozymes, Vertera® ProBite will address and resolve the primary consumer concerns of texture and long ingredient lists and encourage more individuals to make the switch from traditional meat to plant-based alternatives.

"This product launch represents a significant milestone in the plant-based meat sector. Vertera® ProBite has the potential to redefine the consumer experience by improving the texture issue and at the same time enable a more consumer-friendly label. Two areas which are still hindering the widespread adoption of plant-based alternatives," said Birgitte Schou Borch, Head of the Plant & Food Business, Novozymes. 

Vertera® ProBite is an innovation based on the enzyme MTGase (microbial transglutaminase E.C. 2.3.2.13), designed to enhance the texture of plant-based products. Unlike previous solutions, Vertera® ProBite offers the unique advantage of requiring no labeling, marking a significant breakthrough for the plant-based meat industry.

The key features of Vertera® ProBite include:

  • Texture Enhancement: Vertera® ProBite has been specifically engineered to address the texture issue in plant-based meat products. It delivers an exceptional mouthfeel and consistency, ensuring a more satisfying culinary experience for consumers.
  • Simple label: Vertera® ProBite is approved as a processing aid, with its technological function fully realized during the food processing stage. This innovative approach means that any unintentional but technically unavoidable presence of the enzyme in the final product does not necessitate labeling, which will eliminate potential barriers to market entry by offering transparency and simplicity to consumers and enable to elimination of unwanted texturizers.
  • Ease of Handling: Vertera® ProBite is a liquid product, making it incredibly easy to dose and handle safely during food production. Its user-friendly nature is a boon for food manufacturers seeking efficiency in their operations.

Novozymes is committed to driving innovation in biosolutions and promoting sustainable food choices. Vertera® ProBite is another testament to the company's dedication to making the transition to plant-based diets more accessible and enjoyable for consumers worldwide.

About Novozymes

Novozymes is the world leader in biological solutions. Together with customers, partners, and the global community, we improve industrial performance while preserving the planet's resources and helping build better lives. As the world's largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel, and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow.

 

 NASDAQ OMX: NZYM-B • 6,500 employees • DKK 15 billion turnover • 30+ industries • 700+ products



Media Relations  
Lina Danstrup

Head of External Communications

Phone:





 
 
   
Investor Relations  
Tobias Cornelius Björklund

Head of Investor Relations

Phone:

 

Attachment



EN
28/09/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full announcement in PDF. Attachment

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full annuncement in PDF. Attachment

 PRESS RELEASE

Invitation to the 2026 Annual General Meeting

Invitation to the 2026 Annual General Meeting The Annual General Meeting of Novonesis (Novozymes A/S) will be held on Monday March 23, 2026 at 4:00 pm CET at Gammel Venlighedsvej 14, DK-2970 Hoersholm, Denmark. There will also be access to the meeting from the entrance at Boege Alle 10-12, DK-2970 Hoersholm, Denmark. For further information, please refer to the enclosed invitation to convene the Annual General Meeting, including the agenda and complete proposals. BOARD OF DIRECTORSThe Board of Directors proposes the re-election of Cornelis (Cees) de Jong as Chair of the Board and Heine Da...

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. The Executive Leadership Team members eligible for the Novozymes A/S 2023-2025 incentive program has on February 25, 2026, received the allocated shares. An overview of the number and value of shares allotted is provided...

 PRESS RELEASE

Novonesis delivered strong organic sales growth of 7% in 2025

Novonesis delivered strong organic sales growth of 7% in 2025 COPENHAGEN, Denmark – February 26, 2026. Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall.  Ester Baiget, President & CEO:  “In 2025, we continued to deliver strong organic sales growth. We achieved 7% growth, an adjusted EBITDA margin of 37.1% and a strong cash flow – despite currency headwinds. Growth was broad-based across sales areas and markets, with particularly strong performance in Emerging Markets. As a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch